FDA clears Wyeth cancer drug for fast-track status

08/18/2004 | NYTimes.com

Wyeth says the FDA has given fast-track status for its drug, temsirolimus, designed to treat patients with advanced kidney cancer. The drug, currently in a phase III trial studying its survival benefit, prevents the enzyme, rapamycin kinase, from signaling a cancer cell to divide.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA